SHEYLA RANDLE: Open Payments
NPI 1992292528 · PEARLAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$939 in 58 payments from 14 companies in 2025. Trend: 2023 $802 · 2024 $929 · 2025 $939
Food & beverage: $939
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $216 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $153 |
| Alkermes, Inc. | 6 | $110 |
| Neurocrine BioSciences, Inc. | 4 | $98 |
| E.R. Squibb & Sons, L.L.C. | 3 | $68 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Vanda Pharmaceuticals Inc. | 2 | $43 |
| Supernus Pharmaceuticals, Inc. | 2 | $39 |
| Neos Therapeutics, LP | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $33 |
Products named: VRAYLAR, CAPLYTA, ARISTADA, INGREZZA, REXULTI, COBENFY, FANAPT, Qelbree.
Industry payments across TX — which companies pay providers there.
